China Medical Device Innovation Policy 2026: Priority Review, AI Registration Reform & the 10 NMPA Measures

January 2026 brought new urgency to China's medical device innovation agenda. At a high-profile regulatory summit in Shanghai, NMPA officials outlined concrete implementation steps under 国办发[2024]53号 — the State Council directive that puts high-end medical device innovation at the center of healthcare reform. The measures are specific, actionable, and directly affect how innovative devices — foreign and domestic alike — navigate the path from prototype to market. This article decodes what has changed and what it means for companies seeking NMPA registration.

The 10 NMPA Reform Measures for High-End Device Innovation

NMPA has translated the 53号文 mandate into ten operational priorities. Together they represent the most comprehensive overhaul of the innovative device registration framework since the 2021 Regulations:

Priority Review: Which Devices Are Named

The 53号文 framework names specific high-end device categories for priority review. Beyond the broad categories (surgical robots, BCI, radiation therapy, imaging), NMPA has published a detailed list of specific new product types eligible for priority treatment. These represent the frontier of China's domestic substitution and innovation agenda:

Clinical Trial Protocol Pre-Review: A New Risk Reduction Tool

One of the most practically valuable new mechanisms is the clinical trial protocol pre-review for innovative devices. Previously, companies could design and execute a clinical trial, only to discover during technical review that the protocol had structural deficiencies — wasting years of trial data.

Under the new process: after completing preclinical development and a feasibility trial, innovative device applicants can apply to CMDE (器审中心) for a pre-review of their clinical trial protocol through the dedicated "major technical issues consultation" channel. CMDE will review the protocol and issue an opinion that serves as a binding reference point for subsequent technical review. This eliminates one of the most expensive failure modes in the China registration pathway.

AI Medical Device Registration: Four Specific Reforms

AI medical devices have become China's fastest-growing innovative device segment — with over 108 AI products approved as of 2024. NMPA has now introduced four targeted reforms to address the unique challenges of AI device regulation:

1. Multi-Disease & Large-Model AI Guidance

New technical guidance principles are being developed specifically for AI devices that cover multiple disease indications simultaneously, and for large-model AI systems — recognizing that traditional single-indication review frameworks are inadequate for foundation model-based diagnostic tools.

2. Simplified Change Registration for Performance-Optimized AI

When an AI device's core algorithm is unchanged but its performance metrics have improved through retraining or fine-tuning, NMPA will accept a simplified change registration — rather than a full new registration. This removes a major disincentive to continuous AI model improvement and real-world performance refinement after initial approval.

3. Testing Database Methodology for AI Performance Evaluation

NMPA is formalizing the use of curated testing databases as a standardized methodology for evaluating AI device performance — providing a reproducible, regulator-validated benchmark approach that reduces the burden of bespoke clinical study design for performance claims.

4. Cross-Platform Registration Simplification

If an AI software function is registered on one platform, and a manufacturer seeks registration of the same function on a different platform, demonstrating platform equivalence will allow simplified review — eliminating the need to repeat the full technical evidence package for each deployment environment.

Standards Development: Building the Regulatory Foundation

China's 14th Five-Year Plan for pharmaceutical and medical device industry development identified a critical structural weakness: domestic device manufacturers have strong engineering capabilities but weak basic research foundations, leading to homogeneous competition on established technology pathways rather than genuine frontier innovation.

The standards response addresses this at the infrastructure level. NMPA is establishing new standardization technical organizations specifically for AI medical devices and medical robots — China-led standards bodies that will shape how these technologies are evaluated globally, not just domestically. For TCM diagnostic equipment, a dedicated standards development track acknowledges that this category cannot be assessed through frameworks designed for conventional medical physics.

The practical implication: manufacturers entering these categories now are participating in standards formation, not just standards compliance. Early engagement with the standards process — through participation in technical committees, pilot evaluations, and pre-submission consultations — creates a durable regulatory advantage.

Inspection Reforms: Green Channel & Merged Audits

Two operational reforms directly reduce time and cost in the registration process:

• Green channel for innovative device testing: Clinically urgent innovative devices receive immediate-intake, priority testing at designated inspection institutes — eliminating queuing delays that previously added months to registration timelines.
• Merged inspections: Companies that manufacture both Class I devices and Class II/III devices at the same facility can now undergo a single merged GMP inspection, rather than separate inspections for each license tier. This is a significant operational efficiency for platform device companies.

Post-Market Vigilance: Intelligent Monitoring for Novel Risks

Innovative devices present adverse event patterns that differ fundamentally from mature device categories — failures may manifest later, in different populations, or in interaction with novel care pathways. NMPA is upgrading its adverse event monitoring platform with risk profiles specific to innovative devices, and introducing active post-market surveillance requirements (主动监测) for products approved via the innovative device pathway.

For manufacturers, this means the post-market commitment is now more explicit at the time of registration — and more systematic. Companies that build proactive pharmacovigilance systems before registration approval are better positioned for post-market compliance than those that treat vigilance as an afterthought.

What This Means for Foreign Manufacturers

The 2026 reform package creates a more navigable but also more demanding environment for foreign innovative device companies in China:

• Earlier engagement is now rewarded. The clinical trial pre-review mechanism, regional consultation channels, and pre-submission expert consultations all create structured touchpoints where regulatory risk can be identified and resolved before it becomes registration-blocking.
• Named priority categories create a clear targeting framework. Companies in BNCT, ultra-high-field MRI, implantable BCI, transcatheter tricuspid valve, and ECMO should explicitly seek priority review designation — it is not automatic.
• AI device reforms open a window for platform strategy. The cross-platform simplification and change registration reforms make it viable to register an AI platform in China and then iterate — rather than treating each model version or deployment environment as a new registration exercise.
• Standards participation is now strategic. Foreign companies that participate in China's AI and medical robot standards development have an opportunity to shape the framework that will govern their products' review — a level of regulatory influence rarely available in mature markets.

FAQ

2026年中国医疗器械创新政策：优先审评新品类、AI注册改革与NMPA十项举措全解析

2026年1月，中国医疗器械创新议程再度提速。在上海举行的监管峰会上，NMPA官员系统阐述了国办发〔2024〕53号文的具体落实举措——这份国务院文件将高端医疗器械创新置于医改核心位置。相关措施具体、可操作，直接影响着境内外创新器械企业从样机到上市的全链路。本文解析政策变化及其对NMPA注册申报的实际影响。

NMPA高端创新器械十项改革举措

NMPA将53号文任务转化为十项操作重点，这是2021年《条例》出台以来创新器械注册框架最全面的调整：

优先审评：明确点名的具体品类

53号文明确了高端器械优先审评的大类方向，NMPA进一步发布了具体新品类清单，代表中国国产替代和创新议程的前沿：

临床试验方案预审查：重要的风险降低新机制

新设立的临床试验方案预审查机制是实操价值最高的改革之一。此前，企业完成临床试验后才可能在技术审评中发现方案存在根本性缺陷，导致多年试验数据无效。

新流程下：完成产品临床前研发和可行性临床试验后，创新器械申请人可通过器审中心开设的"创新产品重大技术问题咨询沟通"渠道申请临床试验方案预审查，器审中心审查后出具意见，作为后续技术审评的重要参考依据。这从根本上消除了中国注册路径中成本最高的失败模式之一。

AI医疗器械注册：四项专项改革

AI医疗器械已成为中国增长最快的创新器械品类——截至2024年底已有逾108款AI产品获批。NMPA针对AI器械监管的特殊挑战推出四项改革：

一、多病种与大模型AI指导原则

专门针对覆盖多适应证的AI器械和大模型AI系统制定新技术指导原则，承认传统单适应证审评框架不适用于基础模型类诊断工具。

二、核心算法不变时性能优化的简化变更注册

当AI器械核心算法不变、仅通过再训练或微调优化性能指标时，NMPA接受简化变更注册而非重新注册。这消除了持续改进AI模型的重大制度障碍。

三、测评数据库方法用于AI性能评价

NMPA正式将精选测评数据库列为AI器械性能评价的标准化方法，提供可重复、经监管机构验证的基准评估路径，降低每款产品单独设计临床研究的负担。

四、跨平台注册简化

同一AI软件功能已在某平台注册，申请在其他平台注册时，只要能证明平台等同性，即可适用简化审评，无需重复提交完整技术证据包。

标准体系建设：监管基础设施升级

《"十四五"医药工业发展规划》明确指出国内器械企业的结构性短板：工程能力强、基础研究弱，导致在成熟技术路径上同质化竞争，缺乏真正的前沿创新。

标准体系建设从基础设施层面回应这一问题。NMPA专门为AI医疗器械和医用机器人建立标准化技术组织——这是中国主导制定的标准机构，将影响这两类技术的全球评价框架，而不仅限于国内。对参与这些品类的企业而言，现在介入即意味着参与标准制定而非仅仅合规——是获取持久监管竞争优势的战略窗口。

检查改革：绿色通道与合并检查

• 创新器械优先检验绿色通道：临床急需创新器械在指定检验机构享有即收即检待遇，消除此前可能导致数月延迟的排队积压。
• 合并检查：同时生产一类器械的二类、三类器械生产企业，可开展合并GMP检查，无需针对每个许可层级分别检查，大幅降低平台型器械公司的合规成本。

上市后警戒：创新器械智能化监测

创新器械的不良事件模式与成熟器械品类存在根本差异——失效可能发生更晚、出现在不同人群，或与新型诊疗路径交互触发。NMPA正升级不良事件监测平台，建立创新器械专属风险特征档案，并对通过创新路径批准的产品提出主动上市后监测要求（主动监测）。

对企业而言，上市后承诺将在注册批准时就更加明确和系统化。在注册获批前即建立主动警戒体系的企业，上市后合规状态将显著优于将警戒视为事后工作的企业。

对境外企业的战略启示

• 早期接触已有制度回报。临床试验方案预审查、区域沟通渠道和申报前专家咨询，提供了在问题成为注册阻碍之前发现并解决的结构化触点。
• 点名优先品类提供了清晰的目标框架。处于BNCT、超高场MRI、植入式BCI、经导管三尖瓣及ECMO领域的企业应主动申请优先审评认定。
• AI器械改革为平台策略开放了窗口。跨平台简化和变更注册改革，使在中国以AI平台为基础进行迭代注册成为可行路径。
• 标准参与已具战略意义。参与中国AI和医用机器人标准制定的境外企业，有机会塑造未来审评其产品的监管框架。

常见问题